Genmab's successful CEO dismisses retirement plans

Wednesday, Genmab CEO Jan van de Winkel presented yet another guidance upgrade. Even though he has passed 60 years of age, he underscores his intention to remain on board with the company for many years yet.

Photo: PR / Genmab

This Wednesday was in many ways "just another day at the office" for Genmab Chief Executive Jan van de Winkel.

After leading the successful biotechnology company for more than ten years, the Dutch national, who in 2010 was described by some as a possible interim chief, is familiar with booking guidance upgrades and sending good news to shareholders.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs